Zoran Zdraveski
General Counsel at TSCAN THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-05-30
Profile
Dr. Zoran Zdraveski is a Secretary & Chief Legal Officer at TScan Therapeutics, Inc. Dr. Zdraveski was previously employed as a Secretary & Chief Legal Officer by Magenta Therapeutics, Inc. and a Vice President & Associate General Counsel by Epizyme, Inc. He received his undergraduate degree from Southern Methodist University, a graduate degree from Suffolk University Law School and a doctorate degree from Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
0.49% | 2024-03-30 | 238,436 ( 0.49% ) | 2 M $ | 2024-05-30 |
Zoran Zdraveski active positions
| Companies | Position | Start |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | General Counsel | 2021-09-08 |
Former positions of Zoran Zdraveski
| Companies | Position | End |
|---|---|---|
| MAGENTA THERAPEUTICS | General Counsel | 2021-03-31 |
| EPIZYME, INC. | Corporate Officer/Principal | 2017-03-31 |
Training of Zoran Zdraveski
| Massachusetts Institute of Technology | Doctorate Degree |
| Suffolk University Law School | Graduate Degree |
| Southern Methodist University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Zoran Zdraveski
